Offer - Urjas Oil for just ₹ 1 X
Nebi 2.5 Tablet is a commercial drug that is prescribed in the form of Tablet. It is typically used for the treatment of High BP.
The optimal dosage of Nebi 2.5 Tablet is largely dependent on the individual's body weight, medical history, gender and age. Individual symptoms and route of administration also determines the right dosage. Refer to the dosage section for a detailed discussion.
Apart from the aforementioned side effects, Nebi 2.5 Tablet can also lead to other problems, which have been listed below. Usually, these side effects of Nebi 2.5 Tablet go away soon, and do not persist beyond the duration of the treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Nebi 2.5 Tablet has a Severe effect for pregnant women and Severe effect on lactating mothers. Further, the section on Nebi 2.5 Tablet related warnings talks about Nebi 2.5 Tablet's effects on the liver, heart and kidney.
Individuals suffering from medical conditions like Diabetes, Asthma, COPD (Chronic Obstructive Pulmonary Disease) must refrain from the use of Nebi 2.5 Tablet since this can cause severe adverse effects. Other conditions have been mentioned below in the Nebi 2.5 Tablet contraindications section.
Additionally, Nebi 2.5 Tablet may also adversely react with other medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Nebi 2.5 Tablet is considered not safe while driving, and is not addictive.
Nebi 2.5 Tablet is used to treat the following -
Main Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Nebi 2.5 Tablet safe for pregnant women?
Nebi can cause severe side effects if taken during pregnancy, so, pregnant women should talk to their doctor before taking it.
Is the use of Nebi 2.5 Tablet safe during breastfeeding?
Women who are breastfeeding may experience severe harmful effects after taking Nebi. It should only be taken after medical advice.
What is the effect of Nebi 2.5 Tablet on the Kidneys?
Very few cases of side effects of Nebi on kidney have been reported.
What is the effect of Nebi 2.5 Tablet on the Liver?
Nebi is rarely harmful for the liver.
What is the effect of Nebi 2.5 Tablet on the Heart?
Very few cases of side effects of Nebi on the heart have been reported.
Nebi 2.5 Tablet should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
Mild
If you are suffering from any of the following diseases, you should not take Nebi 2.5 Tablet unless your doctor advises you to do so -
Is this Nebi 2.5 Tablet habit forming or addictive?
Forming a habit of Nebi 2.5 Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
After taking Nebi 2.5 Tablet you may feel sleepy. So it is not advised to perform these activities.
Is it safe?
Nebi 2.5 Tablet is safe but it is important to consult a doctor before taking it.
Is it able to treat mental disorders?
Nebi 2.5 Tablet is unable to treat or cure mental disorders.
Interaction between Food and Nebi 2.5 Tablet
When consumed with certain foods, Nebi 2.5 Tablet may take longer to have an effect. Contact your doctor about this.
Interaction between Alcohol and Nebi 2.5 Tablet
Taking alcohol with Nebi 2.5 Tablet can be dangerous.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Bystolic® (nebivolol)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 149-151
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 896-897